Markey home to two breakthrough therapeutic cancer vaccine trials
Findings presented at the IASLC 2024 World Conference on Lung Cancer demonstrated that patients with extensive-stage SCLC (ES‑SCLC) treated with the ADC at a dose of 8.0 mg/kg (n = 31) achieved an overall response rate (ORR) of 61.3% (95% CI, 42.2%–78.2%)
...
...
Evidence level: Állatkísérletes. Állatmodellben vizsgálták.
Related signals
- Extensive-stage Small Cell Lung Cancer - Gallipoli Medical Research
- EGFR-mutant transformed small cell lung cancer harbors intratumoral heterogeneity targetable with MEK inhibitor combination therapy
- Treatment of Small‑Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians Guideline
- Does maintenance/consolidation chemotherapy have a role in the management of small cell lung cancer (SCLC)? A metaanalysis of the published controlled trials.
- Cancer's protective shield: Blocking a signaling pathway could make small cell lung tumors visible to T cells